Intervention Review

You have free access to this content

Temozolomide for high grade glioma

  1. Michael G Hart1,*,
  2. Ruth Garside2,
  3. Gabriel Rogers3,
  4. Ken Stein4,
  5. Robin Grant5

Editorial Group: Cochrane Gynaecological Cancer Group

Published Online: 30 APR 2013

Assessed as up-to-date: 6 MAR 2013

DOI: 10.1002/14651858.CD007415.pub2


How to Cite

Hart MG, Garside R, Rogers G, Stein K, Grant R. Temozolomide for high grade glioma. Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD007415. DOI: 10.1002/14651858.CD007415.pub2.

Author Information

  1. 1

    Department of Neurosurgery, Academic Division of Neurosurgery, Department of Clinical Neurosciences, Cambridge, UK

  2. 2

    University of Exeter Medical School, University of Exeter, European Centre for Environment and Human Health, Truro, UK

  3. 3

    National Institute for Health and Clinical Excellence, Centre for Clinical Practice, Manchester, UK

  4. 4

    University of Exeter Medical School, University of Exeter, Peninsula Technology Assessment Group (PenTAG), Exeter, UK

  5. 5

    Western General Hospital, Edinburgh Centre for Neuro-Oncology (ECNO), Edinburgh, Scotland, UK

*Michael G Hart, Academic Division of Neurosurgery, Department of Clinical Neurosciences, Department of Neurosurgery, Box 167, Addenbrookes Hospital, Cambridge, CB2 0QQ, UK. mikehart82@me.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 30 APR 2013

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Athanassiou 2005 {published data only}
  • Athanassiou H, Synodinou M, Maragoudakis E, Paraskevaidis M, Verigos C, Misailidou D, et al. Randomised phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. Journal of Clinical Oncology 2005;23(10):2372-77.
BR12 2010 {published data only}
  • Brada M,  Stenning S,  Gabe R, Thompson LC,  Levy D,   Rampling R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. Journal of Clinical Oncology 2010;28(30):4601-10.
Clarke 2009 {published data only}
  • Clarke JL, Iwamoto FM, Sul J, Panageas K, Lassman AB, DeAngelis LM, et al. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. Journal of Clinical Oncology 2009;27(23):3861-7.
EORTC/NCIC 26981-22981 {published data only}
  • Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine 2005;352(10):987-96.
  • Stupp R,   Hegi ME,   Mason WP,   van den Bent MJ,   Taphoorn MJ,   Janzer RC, et al and European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups and National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology 2009;10(5):459-66.
  • Taphoorn MJ, Stupp R, Coens C, Osoba D, Kortmann R, van den Bent MJ, et al. Health-related quality of life in patients with glioblastoma: A randomised controlled trial. Lancet Oncology 2005;6:937-44.
Kocher 2008 {published data only}
  • Kocher M, Frommolt P,  Borberg SK, Ruhl U, Steingraber M, Niewald M, et al. Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma. Strahlentherapie und Onkologie 2008;184(11):572-9.
NOA-08 2012 {published data only}
  • Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinback JP, Sabel M, Combs SE, Vesper J, Brain C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M, for the NOA-08 Study Group of the Neuro-oncology Working Group (NOA) of the German Cancer Society. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 Randomised ,phase 3 trial. Lancet Oncology 2012;13(7):707-715.
Nordic 2012 {published data only}
  • Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R, for the Nortic Clinical Brain Tumour Study Group (NCBTSG). Temozolomide versus standard 6-week radiotehrapy versus hypofractionated radiotherapy in patients older than 60 years with gliobalastoma: the Nordic randomised, phase 3 trial. Lancet Oncology 2012;13:916-926.
Yung 2000a {published data only}
  • Osoba D, Brada M, Yung WKA, Prados MD. Health related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. Journal of Clinical Oncology 2000;18(7):1481-91.
  • Yung A, Levin VA, Albright A. Randomized trial of temodal (TEM) vs. procarbazine (PCB) in glioblastoma multiforme (GBM) at first relapse. Proceedings of the American Society of Clinical Oncology 2000;18:139.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Bogdahn 2011 {published data only}
  • Bogdahn U, Hau P, Stockhammer G, Venkataramana NK, Mahapatra AK,   Suri A, et al. The Trabedersen Glioma Study Group. Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro-Oncology 2011;13(1):132-42.
Bower 1997 {published data only}
  • Bower M, Newlands ES, Bleehen NM, Brada M, Begent RJ, Calvert H, et al. Multicentre CRC Phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer, Chemotherapy and Pharmacology 1997;40:484-8.
Gilbert 2010 {published data only}
  • Gilbert MR, Wang M, Aldape K, Sorensen G, Mikkelsen T, Bokstein F, et al. RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan (CPT) or dose-dense temozolomide (TMZ) in recurrent glioblastoma (GBM). Neuro-Oncology. Montreal, QC, Canada, 2010; Vol. 12:iv39.
Hamilton 2006 {published data only}
  • Hamilton DA. Adding concomitant and adjuvant temozolomide to radiotherapy dose not reduce health-related quality of life in people with glioblastoma. Cancer Treatment Reviews 2006;32(6):483-6.
Kim 2010 {published data only}
  • Kim IH, Park C-K, Han J-H, Se-Hoon L, Chae YK, Tae MK, et al. Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial. Neuro-Oncology. Montreal, QC, Canada, 2010:iv51.
Lanzetta 2003 {published data only}
  • Lanzetta G, Campanella C, Rozzi A, Nappa M, Costa A, Fedele F, et al. Temozolamide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial. Anticancer Research 2003;23(6D):5159-64.
Lee 2008 {published data only}
  • Lee S-M, Brada M, Stenning S, Thompson L, Gabe R. A randomised trial of procarbazine, CCNU and vincristine (PCV) vs temozolomide (5-day of 21-day schedule) for recurrent high grade glioma (MRC BR-12, ISRCTN83176944). Annals of Oncology. Stockholm, 2008; Vol. 19 (S8):viii2.
Linz 2009 {published data only}
  • Linz U. Commentary on effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology 2009;10:459-66.
Malmstrom 2010 {published data only}
  • Malmstrom A, Poulsen HS, Stragliotto G, Gronberg B, Hansen S, Asklund T, et al. Neoadjuvant temozolomide for grade III and IV astrocytoma: a randomized phase II study. Neuro-Oncology 2010;12(iii):39-40.
Malmstrom 2010b {published data only}
  • Malmstrom A, Gronberg BH, Stupp R, Marosi C, Frappaz HP, Schultz M, et al. Glioblastoma (GBM) in elderly patients: a randomized phase III trial comparing survival in patients treated with 6-week radiotherapy (RT) versus hypofractionated RT over 2 weeks versus temozolomide single-agent chemotherapy. Journal of Clinical Oncology. Chicago, Il, United States, 2010; Vol. 28:18 Suppl 1.
Naboors 2009 {published data only}
  • Naboors LB. NABTT 0306: A randomized phase II trial of EMD 121974 in conjunction with concomitant and adjuvant temozolomide with radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM). Journal of Clinical Oncology: ASCO annual meeting proceedings 2009;27(15S Part 1):87.
Najak 2010 {published data only}
  • Nayak L, Panageas KS, Deangelis LM, Abrey LE, Lassman AB. Radiotherapy (RT) and temozolomide (TMZ) for anaplastic astrocytoma (AA). Neuro-Oncology. Montreal, QC, Canada, 2010:iv77-78.
Newlands 1996 {published data only}
  • Newlands ES, O'Reilly SM, Glaser MG, Bower M, Evans H, Brock C, et al. The Charing Cross Hospital experience with temozolomide in patients with gliomas. European Journal of Cancer 1996;32A:2236-41.
Osoba 2000b {published data only}
Qian 2009 {published data only}
  • Qian ZZ, Wang HQ, Liu XM, Yang SY, Fu Z, Chang Y, et al. A multicenter randomized controlled study of temozolomide in 97 patients with malignant brain glioma. Chinese Medical Journal 2009;89(29):2059-62.
Renard 2010 {published data only}
  • Renard L, Clement PM, Hammoch F, Boterberg T, Verschaeve V, Whenham N, et al. Safety analysis of randomized Belgian phase II trial of extended use of adjuvant temozolomide in newly diagnosed glioblastoma patients. Neuro-Oncology. Maastricht, Netherlands, 2010.
Spiegel 2007 {published data only}
Stupp 2002 {published data only}
  • Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolamide followed by adjuvant temozolamdide. Journal of Clinical Oncology 2002;20(5):1375-82.
van den Bent 2009 {published data only}
  • van den Bent MJ, Brandes AA, Rampling R,  Kouwenhoven MC,  Kros JM,  Carpentier AF, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. Journal of Clinical Oncology 2009;27(8):1268-74.
Wang 2010 {published data only}
  • Wang X-H, Guo L-Y, Ma B, Yang KH, Zhang QN, Cao N, et al. Radiotherapy combined with temozolomide treatment for glioblastoma multiforme: a meta-analysis. Tumour 2010;30(12):1056-64.
Weller 2010 {published data only}
  • Weller M, Tabatabai G, Reifenberger G, Herrlinger U, Pichler J, Schnell O, et al. Dose-intensifed rechallenge with temozolomide: one week on/one week off versus 3 weeks on/one week off in patients with progressive or recurrent gliomblastoma. Journal of Clinical Oncology. 2010; Vol. 28:15 Supply 1.
Wick 2009 {published data only}
  • Wick W,   Hartmann C,   Engel C,   Stoffels,   Felsberg J,   Stockhammer F, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of Clinical Oncology 2009;27(35):5874-80.
Wick 2010 {published data only}
  • Wick W. NOA-08 randomized phase III trial of 1-week-on/1-week-off temozolomide versus involved-field radiotherapy in elderly (older than 65) patients with newly diagnosed anaplastic astrocytoma or glioblastoma (Methusalem). Journal of Clinical Oncology 2010;28(18 Suppl):949.
Yung 1999 {published data only}
  • Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Journal of Clinical Oncology 1999;17(9):2762-71.
Yung 2000b {published data only}
  • Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. British Journal of Cancer 2000;83(5):588-593.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
ANOCEF 2007
Cairncross 2006
  • Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. Journal of Clinical Oncology 24;18:2707-14.
Castillo 2004
  • Castillo MS, Davis FG, Surawica T, Bruner JM, Bigner S, Coons S, et al. Consistency of primary brain tumor diagnoses and codes in cancer surveillance systems. Neuro-epidemiology 2004;23:85-93.
Counsell 1996
Der Simonian 1986
Fowkes 1991
  • Fowkes FGR, Fulton PM. Critical appraisal of published research: introductory guidelines. BMJ 1991;302:1136-40.
Giese 2004
  • Giese A, Kucinski T, Knopp U, et al. Pattern of recurrence following local chemothereapy with b iodegradeable carmustine (BCNU) implant in patients with glioblastoma . Journal of Neuro-oncology 2004 ; 66 :351-360.
GMT Group 2002
  • Glioma Meta-Analysts Trialists (GMT) Group. Chemotherapy for high grade glioma. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD003913]
Grant 2004
  • Grant R. Overview: brain tumour diagnosis and management/Royal College of Physicians Guidelines. Journal of Neurology, Neurosurgery and Psychiatry 2004;75(Suppl 2):18-23.
Hart 2011a
  • Hart MG, Grant R, Metcalfe SE. Biopsy versus resection for high grade glioma. Cochrane Database of Systematic Reviews 2011 , Issue 2. [DOI: 10.1002/14651858.CD002034]
Hart 2011b
Higgins 2009
  • Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Juni 2001
Kaal 2004
Karnofsky 1948
Kleihues 1993
Louis 2007
Mauer 2008
  • Mauer ME, Bottomley A, Taphoorn MJB. Evaluating health-related quality of life and symptom burden in brain tumour patients: instruments for use in clinical trials and clinical practice. Current Opinion in Neurology 2008;21:741-53.
Parmar 1998
Rampling 2005
  • Rampling R, James A, Papanastassoiu V. The present and future management of malignant brain tumours: surgery, radiotherapy, chemotherapy. Journal of Neurology, Neurosurgery and Psychiatry 2005;75(Suppl II):ii24-ii30.
SHS 2006
  • Scottish Health Startistics. Brain and central nervous system cancer. http://www.isdscotland.org/Health-Topics/Cancer/Cancer-Statistics/Brain-and-Central-Nervous-System/. [: http://estras.isdscotland.org/phpprint.php]
van den Bent 2006
  • van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, et al. Adjucant procarbazine, lomustine and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase II trial. Journal of Clinical Oncology 2006;24(18):2715-2722.
Velasquez-Perez 2002
  • Velasquez-Perez L, Jimenez ME. Clinical-Histopathologic Concordance of Tumors of the Nervous System at the Manuel Velasco Suarez National Institute of Neurology and Neurosurgery in Mexico City. Archives of pathology and laboratory medicine 2002;127(2):187-192.
Walker 1978
  • Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. Journal of Neurosurgery 1978;49:333-43.
Walker 2003
  • Walker M, Brown J, Brown K, Gregor A, Whittle IR, Grant R. Practical problems with the collection and interpretation of serial quality of life assessments in patients with malignant glioma. Journal of Neuro-Oncology 2003;63(2):179-86.
Wen 2010
  • Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group [Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM.]. Journal of Clinical Oncology 2010;28(11):1963-72.

References to other published versions of this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Hart 2008
  • Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K. Temozolomide for high grade glioma. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD007415]